Recurrent patterns of dual RB and p53 pathway inactivation in melanoma

Journal of Investigative Dermatology

Volumn 125, Issue 6, 2005, Pages 1242-1251

  Yang, Guang ^a   Rajadurai, Anpuchchelvi ^a   Tsao, Hensin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CDK4; CDKN2A; Genetics; Melanoma p53

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DNA; PROTEIN P53; RETINOBLASTOMA PROTEIN; PROTEIN P16INK4A;

AMINO ACID SUBSTITUTION; ARTICLE; DNA SEQUENCE; EXON; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; EXONS; GENES, P16; HUMANS; MELANOMA; MICE; POLYMERASE CHAIN REACTION; RECURRENCE; RETINOBLASTOMA PROTEIN; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644825279     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23931.x     Document Type: Article

References (30)

1. Bardeesy N, Bastian BC, Hezel A, et al: Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 21:2144-2153, 2001
2. Bartkova J, Lukas J, Guldberg R et al: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483, 1996
3. Castellano M, Pollock PM, Walters MK, et al: CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57:4868-4875, 1997
4. Chin L, Pomerantz J, Polsky D, et al: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11:2822-2834, 1997
5. Daniotti M, Oggionni M, Ranzani T, et al: BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23:5968-5977, 2004
6. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
7. Eskandarpour M, Hashemi J, Kanter L, et al: Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 95:790-798, 2003
8. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023-5032, 1996
9. Hogg D, Liu L, Lassam N: Genetic testing in familial melanoma. In: Nickoloff BJ (ed). Melanoma: Methods and Protocols, Vol. 61: Methods in Molecular Medicine. Totowa, NJ: Humana Press Inc., 2001
10. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994
11. Kamb A, Gruis N, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
12. Kumar R, Rozell BL, Louhelainen J, et al: Mutations in the CDKN2A (p16ink4a) gene in microdissected sporadic primary melanomas. Int J Cancer 75:193-198, 1998a
13. Kumar R, Sauroja I, Punnonen K, et al: Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 23:273-277, 1998b
14. Kumar R, Smeds J, Berggren P, et al: A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 95:388-393, 2001
15. Kumar R, Smeds J, Lundh Rozell B, et al: Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): Homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 9:138-147, 1999
16. Maelandsmo GM, Florenes VA, Hovig E, et al: Involvement of the pRb/p16/cdk4/cyclinD1 pathway in the tumorigenesis of spordic malignant melanomas. Br J Cancer 73:909-916, 1996
17. Ohta M, Nagai H, Shimizu M, et al: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54:5269-5272, 1994
18. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
19. Ramensky V, Bork R Sunyaev S: Human non-synonymous SNPs: Server and survey. Nucleic Acids Res 30:3894-3900, 2002
20. Rizos H, Darmanian AP, Holland EA, et al: Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:41424-41434, 2001
21. Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:115-177, 1998
22. Sharpless NE, Kannan K, Xu J, et al: Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 22:5055-5059, 2003
23. Sunyaev S, Ramensky V, Bork P: Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet 16:198-200, 2000
24. Sunyaev S, Ramensky V, Koch I, et al: Prediction of deleterious human alleles. Hum Mol Genet 10:591-597, 2001
25. Tsao H: Update on familial cancer syndromes and the skin. J Am Acad Dermatol 42:939-969, 2000; quiz 970-972
26. Tsao H, Benoit E, Sober AJ, et al: Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 58:109-113, 1998a
27. Tsao H, Goel V, Wu H, et al: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-341, 2004
28. Tsao H, Zhang X, Benoit E, et al: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-3402, 1998b
29. Walker GJ, Flores JF, Glendening JM, et al: Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-163, 1998
30. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734, 1998